

Daytrana[®] (methylphenidate) – First-time generic

- On June 27, 2022, Viartis launched an [AB-rated](#) generic version of Noven Therapeutics' [Daytrana \(methylphenidate\)](#) transdermal patches.
- Daytrana is approved for the treatment of attention deficit hyperactivity disorder (ADHD).
- Daytrana carries a boxed warning for drug dependence and is a Scheduled II substance.
- Methylphenidate is also available as brand extended-release capsules ([Adhansia XR[™]](#), [Jornay PM[®]](#)); brand extended-release orally disintegrating tablet ([Cotempla XR-ODT[™]](#)); brand extended-release suspension ([Quillivant XR[®]](#)); brand extended-release chewable tablet ([QuilliChew ER[®]](#)); generic extended-release capsules (for the brands, [Aptensio XR[™]](#), [Ritalin LA[®]](#)), generic extended-release tablets (for the brands, [Concerta[®]](#), [Metadate[®] ER](#), [Relexxii[®]](#)); generic oral solution (for the brand, [Methylin[®]](#)); and generic oral tablet (for the brand, [Ritalin[®]](#)).
 - All are indicated for the treatment of ADHD.
 - Ritalin and Ritalin LA are also indicated for the treatment of narcolepsy.